Clinical Trial Update: PF-03446962 in Relapsed or Refractory Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of PF-03446962 in relapsed or refractory urothelial cancer (transitional cell carcinoma of the bladder) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Bladder

Drugs mentioned

• PF-03446962 (PF-03446962)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Transitional Cell Carcinoma of Bladder | Phase 2 | Status: COMPLETED